PMN vs PRTA vs KO vs ARVN vs IONS

For growth investors, Ionis Pharmaceuticals, Inc.

(IONS) is the stronger pick with 33. 9% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate ProMIS Neurosciences, Inc. (PMN) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, The Coca-Cola Company is actually cheaper at 25.

3x.

Over the past 5 years, Ionis Pharmaceuticals, Inc.

(IONS) delivered a total return of +93. 9%, compared to -96. 4% for ProMIS Neurosciences, Inc. (PMN). Over 10 years, the gap is even starker: IONS returned +241. 3% versus PMN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Prothena Corporation plc's 1. 50β — meaning PRTA is approximately -850% more volatile than KO relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 5% for Ionis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ionis Pharmaceuticals, Inc.

(IONS) is pulling ahead at 33. 9% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Arvinas, Inc. grew EPS 53. 8% year-over-year, compared to -922. 2% for ProMIS Neurosciences, Inc.. Over a 3-year CAGR, ARVN leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — IONS leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, The Coca-Cola Company (KO) trades at 25.

3x forward P/E versus 176. 7x for Prothena Corporation plc — 151. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRTA: 130. 3% to $19. 00.

In this comparison, KO (2.

5% yield) pays a dividend. PMN, PRTA, ARVN, IONS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Prothena Corporation plc (PRTA) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, PRTA: -82. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PMN (Healthcare) and PRTA (Healthcare) and KO (Consumer Defensive) and ARVN (Healthcare) and IONS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PMN is a small-cap quality compounder stock; PRTA is a small-cap quality compounder stock; KO is a large-cap quality compounder stock; ARVN is a small-cap quality compounder stock; IONS is a mid-cap high-growth stock. KO pays a dividend while PMN, PRTA, ARVN, IONS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.